Trial Profile
CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 02 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2014 Status changed from not yet recruiting to recruiting.
- 22 Apr 2014 New trial record